Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Unresectable Hormone Receptor-Positive Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06179303
What this trial is testing

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast Carcinoma+3 more
University of Washington 60
Not applicableStudy completedNCT06676436
What this trial is testing

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Cancer
AstraZeneca 204
Early research (Phase 1)WithdrawnNCT06590558
What this trial is testing

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+9 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41